NeoGenomics Introduces AML Express
NeoGenomics, Inc. (NASDAQ: NEO), a frontrunner in oncology testing services, has announced the launch of AML Express, a cutting-edge next-generation sequencing (NGS) assay tailored for acute myeloid leukemia (AML) genetic profiling. This innovative solution is engineered to provide rapid and comprehensive testing for patients diagnosed with AML, thus addressing a significant clinical demand for timely diagnostic results.
Enhancing Clinical Decision-Making
Chris Smith, CEO of NeoGenomics, emphasized the critical role that AML Express plays in modern hematologic assessment. "AML Express enhances our hematologic portfolio by addressing the clinical need for faster testing that informs critical treatment decisions," said Smith. With a turnaround time of three to four days, this test allows physicians to gain insights specific to each patient, informing tailored treatment strategies while simplifying clinicians' decision-making processes.
The Importance of Timely Diagnosis
AML is known to represent approximately one out of three leukemias in adults and is characterized by its aggressive nature, with rapid progression often occurring within weeks. This urgency highlights the importance of fast and precise diagnostic information—something AML Express aims to provide effectively and efficiently. By analyzing a comprehensive panel of genes relevant to AML, this assay significantly reduces the time and costs associated with traditional single-gene tests.
Real-World Impact on Patient Care
Dr. Nathan Montgomery, Vice President of Medical Services at NeoGenomics, further elaborated on the positive impacts of the new test: "Patients with newly diagnosed acute myeloid leukemia are extremely ill at diagnosis and are at risk of life-threatening complications before initiating treatment. AML Express will be an important tool to help patients get the right treatment sooner, which we believe will reduce the length of hospital stays and improve patient outcomes." This assertion underscores the potential benefits of AML Express in providing critical insights for effective medical intervention.
Compliance with Clinical Guidelines
AML Express aligns seamlessly with recent guidelines established by the European LeukemiaNet, which are also recognized by the National Comprehensive Cancer Network (NCCN). These guidelines represent the evolving standards for diagnosing and treating leukemia, further establishing NeoGenomics' commitment to providing relevant and clinical-quality tests. The new panel significantly broadens the company’s specialized hematology offerings, which include various tests aimed at empowering healthcare providers with the tools necessary to make informed clinical decisions.
About NeoGenomics, Inc.
Founded with the vision of advancing cancer diagnostics, NeoGenomics, Inc. specializes in providing comprehensive cancer genetics testing and informational services. The company offers an extensive selection of oncology-focused tests designed to support physicians in diagnosing and effectively treating cancer.
Headquartered in Fort Myers, Florida, NeoGenomics operates multiple CAP-accredited and CLIA-certified laboratories across the United States and the United Kingdom, ensuring high standards in the processing and analysis of patient samples. Their diverse clientele includes pathologists, oncologists, academic institutions, healthcare systems, and pharmaceutical companies, reflecting the company's robust presence in the oncology testing landscape.
Frequently Asked Questions
What is AML Express?
AML Express is a next-generation sequencing assay by NeoGenomics that delivers rapid genetic profiling for patients with acute myeloid leukemia.
How fast are the results from AML Express?
The turnaround time for AML Express is just three to four days, offering timely insights critical for treatment decisions.
What is the significance of genetic profiling in AML?
Genetic profiling helps identify specific genetic alterations in AML, aiding doctors in determining the most effective treatment options for patients.
How does AML Express align with clinical guidelines?
AML Express adheres to the latest guidelines from the European LeukemiaNet and the NCCN, ensuring contemporary relevance in testing standards.
Who can benefit from AML Express?
Patients diagnosed with acute myeloid leukemia can benefit from this rapid testing service, as it aids in guiding timely and tailored treatment strategies.
